Loxo Oncology's quick rise media-interactive
Loxo Oncology is awaiting U.S. approval of its drug, larotrectinib, that appears to be highly effective against a wide range of solid tumor cancers that share a rare genetic mutation. embed code and instructions: https://reut.rs/2IpfYya
